Skip to Content
Merck
CN
  • Reduced symmetric dimethylation stabilizes vimentin and promotes metastasis in MTAP-deficient lung cancer.

Reduced symmetric dimethylation stabilizes vimentin and promotes metastasis in MTAP-deficient lung cancer.

EMBO reports (2022-06-30)
Wen-Hsin Chang, Yi-Ju Chen, Yi-Jing Hsiao, Ching-Cheng Chiang, Chia-Yu Wang, Ya-Ling Chang, Qi-Sheng Hong, Chien-Yu Lin, Shr-Uen Lin, Gee-Chen Chang, Hsuan-Yu Chen, Yu-Ju Chen, Ching-Hsien Chen, Pan-Chyr Yang, Sung-Liang Yu
ABSTRACT

The aggressive nature and poor prognosis of lung cancer led us to explore the mechanisms driving disease progression. Utilizing our invasive cell-based model, we identified methylthioadenosine phosphorylase (MTAP) and confirmed its suppressive effects on tumorigenesis and metastasis. Patients with low MTAP expression display worse overall and progression-free survival. Mechanistically, accumulation of methylthioadenosine substrate in MTAP-deficient cells reduce the level of protein arginine methyltransferase 5 (PRMT5)-mediated symmetric dimethylarginine (sDMA) modification on proteins. We identify vimentin as a dimethyl-protein whose dimethylation levels drop in response to MTAP deficiency. The sDMA modification on vimentin reduces its protein abundance but trivially affects its filamentous structure. In MTAP-deficient cells, lower sDMA modification prevents ubiquitination-mediated vimentin degradation, thereby stabilizing vimentin and contributing to cell invasion. MTAP and PRMT5 negatively correlate with vimentin in lung cancer samples. Taken together, we propose a mechanism for metastasis involving vimentin post-translational regulation.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
PRMT5/MEP50 Active human, recombinant, expressed in FreeStyle 293-F cells, ≥60% (SDS-PAGE)
Sigma-Aldrich
Anti-PRMT5 Antibody, Upstate®, from rabbit
Sigma-Aldrich
Anti-HA Tag Antibody, Upstate®, from mouse